Skip to Main Content
The first stop for professional medicines advice

Training and Development

82 results

Applied filters

Understanding polypharmacy, overprescribing and deprescribing

21 July 2026We explore the causes, consequences and tools to support pharmacy professionals in managing polypharmacy, overprescribing and deprescribing in practice.

Resources to support medication review

24 July 2026These resources provide information and guidance that reflects the growing understanding of problematic polypharmacy and overprescribing.

Questions to ask when giving medicines advice in renal impairment

29 July 2026Information should be gathered about the renal impairment history or type of kidney disease to enable a risk assessment and decisions about treatment.

Responding to medication safety alerts and notifications

31 July 2026Organisations are issued with a variety of medication safety alerts and notifications, all of which require appropriate responses.

Responding to medication incidents

26 June 2026Practical guidance to support those responding to medication incidents.

SMRs in problematic polypharmacy: case based discussions

20 August 2026Recordings and podcasts of case based discussions about structured medication reviews in problematic polypharmacy, each focussing on a different condition.

Pharmacogenomics in primary care and community pharmacy podcasts

10 September 2026Podcasts exploring how pharmacogenomics is supporting personalised prescribing and shaping the future of medicines optimisation in primary care.

Patient Group Directions e-learning programme

5 May 2026E-learning developed by SPS in partnership with UKHSA, HEE and eLfH to support professionals who use, develop, authorise, review or update PGDs.

Calculating kidney function

16 April 2024We explain the different methods and their limitations that are used to measure kidney function. These methods are not interchangeable.

Calculating and using the Child-Pugh score

14 June 2024The Child-Pugh score is used to estimate the severity of liver disease in patients with cirrhosis, and by drug manufacturers to suggest dose adjustments.